moksha8 entered an exclusive distribution and marketing agreement in Mexico for VESANOID® a CHEPLAPHARM product
moksha8 and CHEPLAPHARM, a family owned pharmaceutical company based in Germany, have recently stepped up their relationship, signing a licensing deal that will see moksha8 take responsibility for the import, distribution, marketing and sale of VESANOID® in Mexico.
VESANOID® contains the ingredient Tretinoin and is applied in the treatment of a special form of leukemia, the Acute Promyelocytic Leukemia (APL) which is a subtype of the Acute Myeloid Leukemia (AML)
moksha8 Attains Brainsway Regulatory Approval for Marketing Deep TMS in Mexico
Brainsway Ltd. (TASE:BRIN), the leader in the development of advanced noninvasive treatments for brain disorders, announced that it has received local regulatory approval for the marketing and distribution of Brainsway Deep TMS (Transcranial Magnetic Stimulation) in Mexico. The company entered an exclusive distribution and marketing agreement with Moksha8, a leading specialty pharmaceutical company in Latin America, who has exclusive rights to distribute Deep TMS in Mexico.
“At least 15 million Mexicans suffer from a mental illness, many of whom do not have access to quality care,” said David Zacut, chief executive officer of Brainsway. “Our technology has been well-received globally, and we are confident that together with Moksha8 we will be able to provide hope to the people of Mexico.”